| 12509442 |
KIF18A inhibitors |
Nuria A. Tamayo, Abhisek Banerjee, James Brown, Michael J. Frohn, Jian-Hua Chen +8 more |
2025-12-30 |
|
| 12473289 |
Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Ning Chen, Clifford GOODMAN +11 more |
2025-11-18 |
|
| 12459932 |
KIF18A inhibitors |
Nuria A. Tamayo, Abhisek Banerjee, James Brown, Michael J. Frohn, Jian-Hua Chen +12 more |
2025-11-04 |
|
| 12440491 |
KRAS G12C inhibitors and methods of using the same |
John Gordon Allen, Jennifer R. Allen, Ana Elena Minatti, Qiufen Xue, Ryan Wurz +22 more |
2025-10-14 |
|
| 12083121 |
Substituted piperazines as KRAS G12C inhibitors |
John Gordon Allen, Brian Alan LANMAN, Jian Chen, Anthony B. Reed, Victor J. Cee +21 more |
2024-09-10 |
$469,902,000 |
| 12054476 |
KIF18A inhibitors |
Nuria A. Tamayo, Abhisek Banerjee, James Brown, Michael J. Frohn, Jian Chen +8 more |
2024-08-06 |
$230,384,000 |
| 11766436 |
KRAS G12C inhibitors and methods of using the same |
John Gordon Allen, Jennifer R. Allen, Ana Elena Minatti, Qiufen Xue, Ryan Wurz +22 more |
2023-09-26 |
$282,576,000 |
| 11285156 |
Substituted piperazines as KRAS G12C inhibitors |
John Gordon Allen, Brian Alan LANMAN, Jian Chen, Anthony B. Reed, Victor J. Cee +21 more |
2022-03-29 |
$231,793,000 |
| 11279712 |
Macrocyclic compounds that inhibit MCL-1 protein |
Sean P. Brown, Yunxiao Li, Paul E. Harrington, Brian Alan LANMAN, Jonathan D. Low +2 more |
2022-03-22 |
$646,313,000 |
| 11090304 |
KRAS G12C inhibitors and methods of using the same |
John Gordon Allen, Jennifer R. Allen, Ana Elena Minatti, Qiufen Xue, Ryan Wurz +22 more |
2021-08-17 |
$335,995,000 |
| 11053226 |
KRAS G12C inhibitors and methods of using the same |
Youngsook Shin, Victor J. Cee, Christopher M. Tegley, Brian Alan LANMAN, Ryan Wurz +5 more |
2021-07-06 |
$240,126,000 |
| 10889581 |
Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Jian Chen, Michael J. Frohn +5 more |
2021-01-12 |
$484,084,000 |
| 9611261 |
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Ana Elena Minatti, Jonathan D. Low, Jennifer R. Allen, Albert Amegadzie, James Brown +12 more |
2017-04-04 |
$276,197,000 |
| 9550762 |
Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, James Brown, Jian Chen +21 more |
2017-01-24 |
$492,282,000 |
| 9096527 |
TRPM8 antagonists and their use in treatments |
Kaustav Biswas, James Brown, Jian Chen, Vijay Keshav Gore, Scott Harried +8 more |
2015-08-04 |
$114,332,000 |
| 9085576 |
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Ana Elena Minatti, Jonathan D. Low, Jennifer R. Allen, Albert Amegadzie, James Brown +12 more |
2015-07-21 |
$288,742,000 |
| 8952009 |
Chroman derivatives as TRPM8 inhibitors |
Kaustav Biswas, Jian Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne +3 more |
2015-02-10 |
$136,135,000 |
| 8883782 |
Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
Yuan Cheng, Ryan White, Albert Amegadzie, James Brown, Alan C. Cheng +19 more |
2014-11-11 |
$176,830,000 |
| 8710043 |
TRPM8 antagonists and their use in treatments |
Jian Chen, Daniel B. Horne, Matthew R. Kaller |
2014-04-29 |
$232,192,000 |
| 8476297 |
TRP-M8 receptor ligands and their use in treatments |
Mark H. Norman, Yunxin Y. Bo, Vijay Keshav Gore, Daniel B. Horne, Matthew R. Kaller +4 more |
2013-07-02 |
$170,066,000 |
| 8426447 |
Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
Ryan White, Albert Amegadzie, Marian C. Bryan, Jian Chen, Alan C. Cheng +14 more |
2013-04-23 |
$145,762,000 |
| 8026241 |
Vanilloid receptor ligands and their use in treatments |
Chenera Balan, Yunxin Y. Bo, Celia Dominguez, Christopher H. Fotsch, Vijay Keshav Gore +6 more |
2011-09-27 |
$234,790,000 |
| 7659276 |
Melanin concentrating hormone receptor antagonist |
Christopher Hulme, Paul Tempest, Thomas Nixey, Guity P. Balow |
2010-02-09 |
$137,549,000 |
| 7582761 |
Vanilloid receptor ligands and their use in treatments |
Chenera Balan, Yunxin Y. Bo, Celia Dominguez, Christopher H. Fotsch, Vijay Keshav Gore +6 more |
2009-09-01 |
$115,395,000 |
| 7514438 |
Melanin concentrating hormone receptor antagonist |
Christopher Hulme, Paul Tempest, Thomas Nixey, Guity P. Balow |
2009-04-07 |
$105,021,000 |